There is record of a clinial trial being carried out on the Australia New Zealand Clinical Trials Registry. It is for a topical solution containing a small molecule currently named SM04554. The trial states that this topical may activate the wnt pathway. Trial was only short and started Sept 2013. I wonder what the outcomes were. There is a contact for public enquiries if someone has time to send them an email - it's on the trial details.
Sounds cool, but is Australia's drug approval process as messed up as the US?. I do not know about yall but I cannot wait much longer for a safe topical AA. Hassan and Wong talked about a topical AA that is suppose to be out this year, but cannot remember the name to it. C'mon man how can you say something like that and get our hopes up. I do not think it is CB because they heard it at a hair loss convention and Cosmo did not deliver any addresses that said it would be out this year.
02-10-2014 11:16 AM
bigentries
Quote:
Originally Posted by deuce
Sounds cool, but is Australia's drug approval process as messed up as the US?. I do not know about yall but I cannot wait much longer for a safe topical AA. Hassan and Wong talked about a topical AA that is suppose to be out this year, but cannot remember the name to it. C'mon man how can you say something like that and get our hopes up. I do not think it is CB because they heard it at a hair loss convention and Cosmo did not deliver any addresses that said it would be out this year.
From the looks of that page, there is recruiting happening in the US at this moment
The Hasson & Wong things ended up being a misunderstanding
And for God's sake, stop with the FDA bitching, save it for a time when a drugs advances to phase III with decent results
02-10-2014 11:44 AM
deuce
Wow so this did not go through any trials yet? Would have been good news about ten years ago, but unfortunately most of us will be bald by the time this comes out. I was not bitching about the FDA just saying it is messed up. As far as H and W. How do you know it was a misunderstanding. Did they say that? Where and when?
02-10-2014 01:01 PM
bigentries
Quote:
Originally Posted by deuce
Wow so this did not go through any trials yet? Would have been good news about ten years ago, but unfortunately most of us will be bald by the time this comes out. I was not bitching about the FDA just saying it is messed up. As far as H and W. How do you know it was a misunderstanding. Did they say that? Where and when?
I asked Dr. Hasson about this a few days ago. He said that there was nothing more to share than what has already been stated. He doesn't know the name of this AA and he heard about it at the ISHRS conference back in October.
Seems like the general consensus is that it was a misunderstanding.
As far as the clinical trial goes, the status says that it is recruiting, but they expected to end enrollment by November last year, so maybe they haven't updated
My bad, it doesn't seem to be any recruitment in the US at the moment, I misinterpreted the "Page 8" and "recruitment outside australia" sections. But it does lists a company in America as the primary sponsor
Still, this stuff seems pretty interesting, the primary sponsor seems connected with WNT research http://www.samumed.com/
02-10-2014 01:58 PM
lilpauly
Quote:
Originally Posted by bigentries
From the looks of that page, there is recruiting happening in the US at this moment
The Hasson & Wong things ended up being a misunderstanding
And for God's sake, stop with the FDA bitching, save it for a time when a drugs advances to phase III with decent results
I agree phase 111 is crucial , most go dead after phase 1 .
02-10-2014 02:03 PM
hellouser
Quote:
Originally Posted by lilpauly
I agree phase 111 is crucial , most go dead after phase 1 .
Many go dead after Phase I too *cough*Aderans,RU58841,neosh,etc*cough*
02-11-2014 11:10 PM
Jens1986
Quote:
Originally Posted by hellouser
Many go dead after Phase I too *cough*Aderans,RU58841,neosh,etc*cough*
PSK 3841, a nonsteroidal
antiandrogen, has completed phase IIa
trials for the treatment of androgenetic
alopecia and a clinical proof-of-concept
study to reduce sebum flow and
secretion in patients with acne. Six
months of treatment with PSK 3481
demonstrated equivalent or better net
hair growth compared with finasteride.
